COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

HCCS reviews applications related to the effects of chronic HIV infection and/or antiretroviral drug therapy on end organ diseases. Studies include basic science studies, animal models, and clinical studies. Examples of end organ disease commonly seen includes cardiomyopathy, renal disease, liver disease, pulmonary dysfunction, neurocognitive and neurological disorders, metabolic complications, and diabetes. The study section also reviews applications involving clinical studies of HIV and aging, clinical management of symptoms and disease progression in children, pregnant women, adults and other defined cohorts.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • The mechanisms involved in CNS dysfunction, neuroimaging, neurological and neurocognitive studies.
  • The biological effects of drug abuse on the CNS and other organs in the context of HIV/AIDS.
  • Basic, clinical, and epidemiological studies of cardiovascular, pulmonary, hematologic, metabolic, digestive diseases and sleep comorbidities as a consequence of HIV infection and/or anti-retroviral treatment.
  • Studies of risk factors and/or biomarkers for HIV associated comorbidities.
  • Basic and clinical studies (with biological outcomes) of the effect of HIV on aging and interactions of the aging processes on HIV progression and comorbidities.
  • The clinical management of symptoms and disease associated with HIV infection in defined cohorts.
  • Clinical studies on the biological effects and efficacy of pre- and post-exposure prophylaxis in adults, including pregnant women, and children.
  • Clinical studies addressing inflammation and its contribution to organ disease in HIV infection and antiretroviral therapy.
  • Non-immunological clinical studies to characterize organ-based viral reservoirs and interventions to eliminate them.
  • Clinical studies on antiretroviral drug side effects and drug resistance including pharmacogenetics.

AARR Overlaps:

Population and Public Health Approaches to HIV/AIDS (PPAH): Epidemiological studies employing biological assays and/or focusing on biological outcomes can be reviewed in HCCS; epidemiological studies employing behavioral measures and/or behavioral outcomes are reviewed in PPAH.

HIV Molecular Virology, Cell Biology, and Drug Development (HVCD): Clinical studies that address biological effects of drug abuse, approaches to characterize and eliminate viral reservoirs, drug resistance and side effects of antiretroviral drugs can be reviewed in HCCS; more basic biological studies employing cell culture and animal models are reviewed in HVCD.

HIV Immunopathogenesis and Vaccine Development (HIVD): HCCS reviews clinical studies that address inflammation and its contribution to HIV-related organ disease, viral reservoirs and interventions to eliminate them, and non-immunological effects of drug abuse on the CNS and other organs in the context of HIV/AIDS; studies addressing immune mechanisms of virus clearance and pathogenesis are reviewed in HIVD.

HIV Coinfections and HIV Associated Cancers (HCAC): Applications that address clinical aspects of HIV associated organ diseases are reviewed in HCCS; clinical studies related to HIV coinfections and/or HIV associated cancers may be reviewed in HCAC. Certain basic biological studies of HIV associated organ diseases employing animal and cell culture models may be reviewed in HCAC.

Non-AARR Overlaps:

Only applications in which there is a clear and compelling HIV/AIDS research component in the proposed research plan are eligible for the AIDS deadlines and review in HCCS and other AARR study sections. Those deemed insufficiently related to HIV/AIDS are assigned to other study sections and must be submitted in time to meet the regular non-AIDS application due dates. Applicants might consider requesting study sections in the following integrated review groups (IRGs):

Brain Disorders and Clinical Neuroscience (BDCN): for example, the Clinical Neuroimmunology and Brain Tumors (CNBT) study section includes studies of CNS infectious diseases and associated pathologies.

Population Sciences and Epidemiology (PSE): for example, the Kidney, Nutrition, Obesity and Diabetes Study (KNOD) study section reviews applications on the epidemiology of kidney, diabetes, obesity, and liver diseases in human populations; the Infectious, Reproductive, Asthma and Pulmonary Conditions (IRAP) study section reviews applications on the epidemiology of infectious diseases, reproductive health, asthma and pulmonary conditions.

Cardiovascular and Respiratory Sciences (CVRS): for example, the Clinical Integrative Cardiovascular and Hematological Sciences (CCHS) study section reviews clinical research involving the cardiovascular system and related regulatory organ systems; the Lung Cellular, Molecular, and Immunobiology (LCMI) study section includes studies on inflammatory and/or immune mechanisms which contribute to the pathogenesis of airway diseases.